Our range of respiratory medicines means we share a common interest with respiratory specialists.
We focus on supporting the NHS and the Department of Health in managing long-term conditions like asthma and chronic obstructive pulmonary disease (COPD). We address cost-efficient prescribing and develop joined-up care through our Joint Working projects to help improve patient outcomes and also offer value for money.
By recognising aligned goals and objectives in areas of mutual interest, we can work jointly to improve patient outcomes and enhance patient experience. That might be through medicines optimisation, quality improvement, pathway redesign or improvement, innovation or identifying cost efficiencies.
Over five million people in the UK are currently receiving treatment for asthma and the NHS is thought to spend over £1 billion each year treating the condition.1
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases in the UK. It is estimated that 3 million people have COPD, of whom 2 million are undiagnosed,2 often because people are reluctant to seek medical help, and perhaps ignore their symptoms.
Around 10,000 people are also living with Cystic Fibrosis, it is one of the UK’s most common life-shortening inherited conditions, affecting around one in 2,500 live births.3
As well as developing and providing our own specialty medicines dedicated to the treatment of asthma, COPD and Cystic Fibrosis, we provide a range of information, consultation and education services to help you manage and improve the service you provide to your patients. This includes inhaler technique training and helping patients understand how compliance and self management of their condition can benefit their overall health.
We work in partnership with multiple Clinical Commissioning Groups across the country to deliver improved patient outcomes. This is through such Joint Working projects as advanced inhaler training, improving patient education and clinical management of asthma and COPD as well as many more projects. Our Joint Working projects are available on our Joint Working pages.
To discuss potential Joint Working opportunities with Teva within respiratory you can contact us and a representative from Teva will be in touch.
Let's Talk Respiratory is our educational programme of supportive materials, resources and some of the latest news in respiratory for both you and your patients.
Our aim is to support you and encourage you, help empower patients and to make a real difference to the lives of those living with asthma and COPD.
1 http://www.asthma.org.uk/asthma-facts-and-statistics accessed 18.04.18
2 https://www.nice.org.uk/guidance/qs10/chapter/introduction accessed 18.04.18
3 https://www.cysticfibrosis.org.uk/what-is-cystic-fibrosis/faqs accessed 18.04.2018
4 DuoResp Spiromax® 320 micrograms/9 micrograms and 160 micrograms/4.5
micrograms inhalation powder - Summary of Product Characteristics
5 Price D et al. Resp Med, 2013; 107: 37–46.
6 Aerivio Spiromax® (salmeterol xinafoate/fluticasone propionate) - Summary of Product Characteristics
7 Braltus Zonda® (tiotropium) - Summary of Product Characteristics
8 Qvar® (CFC free beclometasone dipropionate) - Summary of Product Characteristics
9 Cinqaero® (reslizumab) - Summary of Product Characteristics
10 Tymbrineb® (tobramycin) - Summary of Product Characteristics
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.